5 completed, 3 terminated, 1 withdrawn. 9 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 9 | Completed 5, Terminated 3, Withdrawn 1 |
| Phase 2 | 1 | Completed 1 |
Follow T-Vec: new trials by email Literature Review of T-Vec trials Research Report on T-Vec
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| T-VEC With Chemotherapy or Endocrine Therapy in Treating Participants With HER2- Negative Breast Cancer Anastrozole, Exemestane, Fulvestrant - Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8 | Phase 1 | Completed | University of California, San Francisco | 20 | 2020-02-05 | 2025-05-21 |
| Talimogene Laherparepvec and Panitumumab for the Treatment of Locally Advanced or Metastatic Squamous Cell Carcinoma of the Skin Panitumumab, Talimogene Laherparepvec - Locally Advanced Skin Squamous Cell Carcinoma, Metastatic Skin Squamous Cell Carcinoma | Phase 1 | Terminated | Rutgers, The State University of New Jersey | 5 | 2020-01-31 | 2026-01-23 |
| Ipilimumab, Nivolumab, and Talimogene Laherparepvec Before Surgery in Treating Participants With Localized, Triple-Negative or Estrogen Receptor Positive, HER2 Negative Breast Cancer-deleted Ipilimumab, Nivolumab, Talimogene Laherparepvec - Anatomic Stage 0 Breast Cancer AJCC v8, Anatomic Stage I Breast Cancer AJCC v8 | Phase 1 | Terminated | Jonsson Comprehensive Cancer Center | 6 | 2019-07-10 | 2023-08-15 |
| Talimogene Laherparepvec, Chemotherapy, and Radiation Therapy Before Surgery in Treating Patients With Locally Advanced or Metastatic Rectal Cancer Capecitabine, Fluorouracil, Leucovorin - Locally Advanced Rectal Adenocarcinoma, Metastatic Rectal Adenocarcinoma | Phase 1 | Terminated | National Cancer Institute (NCI) | 3 | 2019-05-14 | 2024-05-23 |
| Talimogene Laherparepvec in Treating Patients With Non-Muscle Invasive Bladder Transitional Cell Carcinoma Laboratory Biomarker Analysis, Talimogene Laherparepvec - Stage 0 Bladder Urothelial Carcinoma AJCC v6 and v7, Stage 0a Bladder Urothelial Carcinoma AJCC v6 and v7 | Phase 1 | Withdrawn | University of California, San Francisco | 2018-06-01 | 2020-07-28 | |
| Study of Talimogene Laherparepvec (T-VEC) in Pancreatic Cancer Talimogene laherparepvec - Pancreatic Cancer | Phase 1 | Completed | Karie D. Runcie, MD | 10 | 2017-11-16 | 2024-11-22 |
| Study to Evaluate the Safety/ Efficacy of T-VEC in Japanese Subjects With Unresectable Stage IIIB-IV Malignant Melanoma Talimogene laherparepvec - Unresectable Stage IIIB-IV Malignant Melanoma | Phase 1 | Completed | Amgen | 18 | 2017-03-07 | 2023-08-09 |
| Ipilimumab With or Without Talimogene Laherparepvec in Unresected Melanoma Talimogene laherparepvec, Ipilimumab - Melanoma | Phase 1 / Phase 2 | Completed | Amgen | 217 | 2013-02-07 | 2024-05-14 |
| Talimogene Laherparepvec in Patients With Unresectable Pancreatic Cancer Talimogene Laherparepvec - Pancreatic Cancer | Phase 1 | Completed | BioVex Limited | 17 | 2006-11-01 | 2016-04-15 |
Pancreatic Neoplasms (2) · Adenocarcinoma (1) · Breast Carcinoma In Situ (1) · Breast Neoplasms (1) · Melanoma (1) · Neoplasm Metastasis (1) · Rectal Neoplasms (1) · Triple Negative Breast Neoplasms (1)
Amgen (2) · University of California, San Francisco (2) · BioVex Limited (1) · Jonsson Comprehensive Cancer Center (1) · Karie D. Runcie, MD (1) · National Cancer Institute (NCI) (1) · Rutgers, The State University of New Jersey (1)
United States (8) · France (1) · Germany (1) · Japan (1)
Adam C Berger, MD, FACS (1) · Amy J Chien, MD (1) · John A Glaspy (1) · Karie Runcie, MD (1) · Nageshwara V Dasari (1) · Neil N Senzer, MD (1) · Robert Coffin, PhD (1) · Terence Friedlander (1)
PMID 37621406, PMID 39673447, PMID 41271741
P30CA072720 (1), UM1CA186688 (1)